David A. Cox
ORCID: 0000-0003-2052-9836
· 1 paper in corpus
OBJECTIVE: The aim of this study was to report the gynecologic safety findings from the Generations trial, a phase 3 study of the selective estrogen receptor modulator (SERM), arzoxifene. METHODS: A predefined objective of the trial was to …